Results 101 to 110 of about 196 (129)

Original nootropic drug Noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade

Bulletin of Experimental Biology and Medicine, 2008
R U Ostrovskaya, Ostrovskaya R U
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats

Biomeditsinskaya Khimiya, 2018
The study of the pharmacokinetics of new drugs and the identification of active metabolites is a necessary step for effective and safe use in the clinical practice. It is especially important for peptide drugs due to their enzymatic instability, low bioavailability and poor permeability through the blood-brain barrier (BBB).
S S, Boyko, V P, Zherdev, R V, Shevchenko   +2 more
openaire   +2 more sources

Effect of Noopept and Afobazole on the Development of Neurosis of Learned Helplessness in Rats

Bulletin of Experimental Biology and Medicine, 2003
We studied the effects of new psychotropic preparations noopept and afobazole on acquisition of the conditioned active avoidance response and development of neurosis of learned helplessness in rats. Noopept in doses of 0.05-0.10 mg/kg accelerated acquisition of conditioned active avoidance response and reduced the incidence of learned helplessness in ...
A A, Uyanaev, V P, Fisenko, N K, Khitrov
openaire   +2 more sources

Nootropic Dipeptide Noopept Enhances Inhibitory Synaptic Transmission in the Hippocampus

Bulletin of Experimental Biology and Medicine, 2015
Application of nootropic agent Noopept on hippocampal slices from Wistar rats enhanced the inhibitory component of total current induced by stimulation of Shaffer collaterals in CA1 pyramidal neurons, but did not affect the excitatory component. A direct correlation between the increase in the amplitude of inhibitory current and agent concentration was
I S, Povarov, R V, Kondratenko, V I, Derevyagin, R U, Ostrovskaya, V G, Skrebitskii   +4 more
openaire   +2 more sources

Neuroprotective Dipeptide Noopept Prevents DNA Damage in Mice with Modeled Prediabetes

Bulletin of Experimental Biology and Medicine, 2019
In experiments on BALB/c mice, prediabetes was modeled by administration of streptozotocin in a dose of 130 mg/kg. DNA damage was assessed by the method of DNA comets. Noopept (0.5 mg/kg intraperitoneally) was administered for 14 days before and for 6, 13, or 14 days after streptozotocin administration.
R U, Ostrovskaya, S S, Yagubova, A K, Zhanataev, E A, Anisina, T A, Gudasheva, A D, Durnev   +5 more
openaire   +2 more sources

[Interspecies differences of noopept pharmacokinetics].

Eksperimental'naia i klinicheskaia farmakologiia, 2004
Significant interspecific differences in the pharmacokinetics of noopept are manifested by a decrease in the drug elimination rate on the passage from rats to rabbits and humans. Very intensive metabolism of noopept was observed upon intravenous administration in rats.
S S, Boĭko, S A, Korotkov, V P, Zherdev, T A, Gudasheva, R U, Ostrovskaia, T A, Voronina   +5 more
openaire   +1 more source

[Preclinical study of noopept toxicity].

Eksperimental'naia i klinicheskaia farmakologiia, 2002
Within the framework of a preclinical investigation, the new nootrope drug noopept (N-phenyl-acetyl-L-propyl-glycine ethylate) was tested for chronic toxicity upon peroral administration in a dose of 10 or 100 mg/kg over 6 months in both male and female rabbits.
L P, Kovalenko, N M, Smol'nikova, S V, Alekseeva, E P, Nemova, A V, Sorokina, M G, Miramedova, S P, Kurapova, E I, Sidorina, A V, Kulakova, N O, Daugel'-Dauge   +9 more
openaire   +1 more source

Developing analytical methods for the creation of the state reference sample of noopept

Pharmaceutical Chemistry Journal, 2007
The physicochemical properties of noopept, a new domestic original drug with nootropic action, have been studied with a view to developing analytical methods, establishing quality criteria for the parent drug substance, and creating the state reference sample (SRS). These methods will be included in a draft of the regulation on the SRS of noopept.
A. V. Gusev, L. N. Grushevskaya, O. B. Stepanenko, N. I. Avdyunina, B. M. Pyatin, V. P. Lezina, O. S. Anisimova   +6 more
openaire   +1 more source

Noopept pharmacokinetics after intravenous administration of a lyophilized medicinal form in rats

Pharmaceutical Chemistry Journal, 2007
The pharmacokinetics of noopept, a dipeptide drug possessing nootropic and neuroprotective properties, were evaluated in rats after the intravenous administration of its novel formulation for injections prepared using lyophilization in the presence of mannitol.
S. S. Boiko, V. P. Zherdev, V. P. Kolyvanov, R. U. Ostrovskaya, T. A. Gudasheva, K. S. Us, S. B. Seredenin   +6 more
openaire   +1 more source

Noopept Reduces the Postischemic Functional and Metabolic Disorders in the Brain of Rats with Different Sensitivity to Hypoxia

Bulletin of Experimental Biology and Medicine, 2009
Chronic cerebral ischemia was induced by ligation of both common carotid arteries in Wistar rats, divided by sensitivity to hypoxia into highly sensitive and low-sensitive. Noopept (peptide preparation), injected (0.5 mg/kg) during 7 days after occlusion of the carotid arteries, reduced the neurological disorders in rats with high and low sensitivity ...
I V, Zarubina, P D, Shabanov
openaire   +2 more sources